Literature DB >> 7844101

Management of comorbid anxiety and depression.

J M Zajecka1, J S Ross.   

Abstract

The coexistence of anxiety and depression is common and frequently poses diagnostic and treatment challenges in the clinical setting. Although precise diagnosis is important for treatment selection, it is often complicated by the shortcomings of the current classification system. Whereas some patients present with symptoms that meet the diagnostic criteria for both an anxiety disorder and major depression, others may present with "subsyndromal" symptoms of depression and/or anxiety. Epidemiologic data and a rational treatment approach to the patient with mixed anxiety and depression, depressive symptoms coexistent with "syndromal" and "subsyndromal" symptoms of generalized anxiety disorder, panic disorder, obsessive compulsive disorder, and social phobia are discussed, as well as areas of future research to examine coexisting anxiety and depression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7844101

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

Review 1.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

2.  Mixed Anxiety and Depression : Diagnosis and Treatment Options.

Authors:  D Bakish; R Habib; C L Hooper
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

3.  Increased miR-132 level is associated with visual memory dysfunction in patients with depression.

Authors:  Ye Liu; Xiao Yang; Liansheng Zhao; Jian Zhang; Tao Li; Xiaohong Ma
Journal:  Neuropsychiatr Dis Treat       Date:  2016-11-09       Impact factor: 2.570

4.  Anxiety and depression are common in rheumatoid arthritis and correlate with poor quality of life in Indian patients.

Authors:  Gurmeet Singh; Nikhil Mahajan; Sameer Abrol; Abhinav Raina
Journal:  Reumatologia       Date:  2022-01-12

5.  Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease.

Authors:  Lana L Watkins; Gary G Koch; Andrew Sherwood; James A Blumenthal; Jonathan R T Davidson; Christopher O'Connor; Michael H Sketch
Journal:  J Am Heart Assoc       Date:  2013-03-19       Impact factor: 5.501

6.  Anxiety and depression in inflammatory eye disease: exploring the potential impact of topical treatment frequency as a putative psychometric item.

Authors:  Georgios Vakros; Paolo Scollo; James Hodson; Philip I Murray; Saaeha Rauz
Journal:  BMJ Open Ophthalmol       Date:  2021-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.